U.S. Markets close in 5 hrs 10 mins

Blog Exposure - FDA Granted Approval to AMAG’s Makena(R) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-risk Women

LONDON, UK / ACCESSWIRE / February 20, 2018 / Active-Investors.com has just released a free research report on AMAG Pharma, Inc. (AMAG) ("AMAG"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AMAG as the Company's latest news hit the wire. On February 14, 2018, the Company announced that the US Food and Drug Administration (FDA) has approved the Makena® (hydroxyprogesterone caproate injection) subcutaneous auto-injector drug-device combination product as a ready-to-administer treatment to reduce the risk of preterm birth in women pregnant who have previously delivered one preterm baby in the past. The FDA accepted supplemental new drug application (sNDA) for Makena in June 2017. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, AMAG Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AMAG

The prefilled Makena® auto-injector offers a new administration option for patients and providers and contains a shorter, thinner non-visible needle compared to the intramuscular (IM) Makena® injection.

Makena® Subcutaneous Auto-Injector to be Available in Second Half of March 2018

Makena® was approved by the FDA in February 2011 and remains the first and only FDA-approved treatment option currently available for pregnant women who have had a prior spontaneous preterm birth. The product's seven-year orphan drug exclusivity expired earlier this month, and the Company does not anticipate a generic version of the IM formulation of Makena® to enter the market until mid-year. The subcutaneous auto-injector will be available in the second half of March 2018. The auto-injector will be priced at parity with the IM formulation to help ensure timely and affordable access.

Additionally, AMAG will file a NDA in Q1 2018 for a new chemical entity (bremelanotide) to treat hypoactive sexual desire disorder (HSDD), a common sexual health condition.

Makena® Auto-Injector Developed in Partnership with Antares Pharma

The Company developed the Makena® auto-injector with its device partner Antares Pharma, Inc., which holds issued patents on the auto-injector device and drug-device combination, the last of which expires in 2034. AMAG also holds a US patent directed to subcutaneous administration and dosing of the Makena® auto-injector product which expires in 2036. AMAG will request Orange Book listing of the eligible AMAG and Antares patents.

AMAG Issued New Patent Directed to Subcutaneous Administration of Makena®

In December 2017, AMAG was issued US Patent Number 9,844,558 entitled "Methods of Reducing Risk of Preterm Birth", directed to subcutaneous administration and dosing of Makena®. The patent is expected to expire on May 02, 2036.

AMAG's Second FDA Approval in February

This approval marks the second FDA approval this month for AMAG. On February 05, 2018, FDA approved the Company's application to broaden the existing label for Feraheme® (ferumoxytol injection) beyond the current chronic kidney disease (CKD) indication to include all eligible adult Iron Deficiency Anemia (IDA) patients who have intolerance to oral iron or have had unsatisfactory response to oral iron. The Feraheme label expansion approval was supported by two positive pivotal Phase-3 trials evaluating Feraheme versus iron sucrose or placebo in a broad population of patients with IDA.

About Makena®

Makena® is a prescription hormone medicine (progestin) used to lower the risk of preterm birth in women who are pregnant with one baby and who have delivered one baby too early in the past. Makena® was shown to work based on a lower number of women who delivered babies at less than 37 weeks of pregnancy. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. Makena® may cause serious side effects including blood clots, allergic reactions, depression, and yellowing of the skin and the whites of the eyes. The most common side effects include injection site reactions (pain, swelling, itching, bruising, or a hard bump), hives, itching, nausea, and diarrhea. The most common side effects reported with the Makena® auto-injector use was injection site pain.

About AMAG Pharmaceuticals, Inc.

Founded in 1981, AMAG is a biopharmaceutical company focused on bringing therapeutics to market that support the health of patients in the areas of maternal health, anemia management, and cancer supportive care. The Company is headquartered in Waltham, Massachusetts, with additional offices in Tucson, Arizona, and San Bruno, California.

Stock Performance Snapshot

February 16, 2018 - At Friday's closing bell, AMAG Pharma's stock advanced 3.06%, ending the trading session at $18.50.

Volume traded for the day: 2.88 million shares, which was above the 3-month average volume of 1.01 million shares.

Stock performance in the last month – up 39.62%; previous three-month period – up 30.28%; past six-month period – up 9.14%; and year-to-date - up 39.62%

After last Friday's close, AMAG Pharma's market cap was at $653.25 million.

The stock is part of the Healthcare sector, categorized under the Diagnostic Substances industry. This sector was up 0.6% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the ''Author'') and is fact checked and reviewed by a third-party research service company (the ''Reviewer'') represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the ''Sponsor''), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors